Acceleron Pharma Inc. XLRN
Set alert
178.75 +178.75 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -54.17
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2021
- 50-d avg
- 169.49
- 200-d avg
- 137.95
- 1y target
- 178.88
Analyst view
Consensus: buy
Buy
Price target (mean) 178.88 +0.1% upside
Now 178.75
- Target (low)
- 171.00
- Target (mean)
- 178.88
- Target (high)
- 180.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 11
- 2 months ago 11
- 3 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.93 | -1.16 – -0.50 | -0.95 | +2.1% | 41.24M | +59.4% | 9 |
| Next quarter | -0.97 | -1.11 – -0.82 | -1.05 | +7.6% | 43.52M | 0.0% | 4 |
| Current year | -4.06 | -4.41 – -3.66 | -2.92 | -39.0% | 131.89M | +42.5% | 9 |
| Next year | -3.30 | -4.46 – -2.72 | -4.06 | +18.7% | 206.00M | +56.2% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2021 | Jefferies | Initiated | — | Hold |
| Oct 4, 2021 | Raymond James | Downgrade | Strong Buy | Market Perform |
| Oct 1, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Oct 1, 2021 | Barclays | Downgrade | Overweight | Equal-Weight |
| Oct 1, 2021 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Sep 30, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 30, 2021 | Piper Sandler | Downgrade | Overweight | Neutral |
| Sep 30, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Sep 27, 2021 | RBC Capital | Maintained | — | Sector Perform |
| Mar 23, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Mar 12, 2021 | Wolfe Research | Initiated | — | Outperform |
| Mar 1, 2021 | Citigroup | Maintained | — | Buy |
| Feb 26, 2021 | Piper Sandler | Maintained | — | Overweight |
| Feb 26, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Feb 26, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jan 29, 2021 | JP Morgan | Maintained | — | Overweight |
| Jan 19, 2021 | Raymond James | Maintained | — | Strong Buy |
| Jan 19, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 16, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Nov 16, 2020 | Oppenheimer | Maintained | — | Outperform |
| Nov 6, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Nov 6, 2020 | SVB Leerink | Maintained | — | Outperform |
| Nov 6, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 13, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Aug 7, 2020 | Credit Suisse | Maintained | — | Outperform |
| Aug 7, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jun 26, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jun 25, 2020 | Credit Suisse | Maintained | — | Outperform |
| Jun 2, 2020 | Citigroup | Maintained | — | Buy |
| May 12, 2020 | JP Morgan | Maintained | — | Overweight |